AbstractAs in the medical biotechnology area some decades ago, the fast technological development within industrial biotechnology (IB) has caused numerous new ventures. Venture capital (VC) has become a major capital source for these companies and VC investors have particularly allocated financing to research and development (R&D) based companies. Since the early 2000s, the global net stock of VC investments in IB companies has continuously increased over the past 12 years and exceeded 3.5 billion US dollars at the end of 2013. In 2013, the gross amount of VC money was 386 million US dollars distributed to 20 companies corresponding to an average amount of 19.3 million US dollars for each company. The rising capital contribution into the IB sector indicates that it is seen as an attractive investment opportunity for VC investors. Analysing the VC investments by segments shows that there is a strong preference for biofuels and biochemicals. The regional breakdown of VC activities shows that the Americas are the leading region followed by Europe.
Coons, R. (2010) Industrial Biotechnology. Chemical Week 172: 22-26.
Festel, G. (2010) Industrial biotechnology: Market size, company types, business models, and growth strategies. Industrial Biotechnology 6: 88-94.
EuropaBio (2003) White Biotechnology: Gateway to a More Sustainable Future. Brussels: EuropaBio.
SusChem (2005) Industrial or White Biotechnology. Brussels: EuropaBio.
Festel, G., Detzel, C. and Maas, R. (2012) Industrial biotechnology â€“ Markets and industry structure. Journal of Commercial Biotechnology 18(1): 11-21.
Hermann, B.G., Blok, K. and Patel, M.K. (2007) Producing Bio-Based Bulk Chemicals Using Industrial Biotechnology Saves Energy and Combats Climate Change. Environmental Science & Technology 41: 7915-7921.
Festel, G., KnÃ¶ll, J. and GÃ¶tz, H. (2004) Industrial Biotech - Influencing Produc-tion. Chemistry & Industry 7: 21-22.
Festel, G. (2011) Drivers and barriers for industrial biotechnology. International Sugar Journal 113(1345): 19-23.
Yang, W. (2014) 2013 - Biotech back in the saddle. Nature Biotech 32: 126-126.
Huggett, B. (2014) Biotech's wellspring: the health of private biotech in 2013. Nature Biotech 32: 428-435.
Unless specified by prior arrangement, the author agrees to the following terms and assurances:
- For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
- I/we further give to the following assurances
- I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
- I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
- To the best of my/our knowledge, all the facts in the contribution are true and accurate;
- The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
- Nothing in the contribution is obscene or libellous;
- Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
- I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).